Summary
Gilead Sciences, Inc. reported robust financial performance for the nine months ended September 30, 2010, demonstrating significant year-over-year growth. Total revenues increased by 19.7% to $5.95 billion, driven primarily by a 17% surge in product sales, reaching $5.46 billion. This growth was largely fueled by strong performances in their antiviral franchise, particularly Atripla and Truvada, which together accounted for over 73% of total product sales in the third quarter. The company also saw a notable increase in cash and cash equivalents, reaching $5.05 billion by the end of the period, supported by strong operating cash flows and proceeds from the issuance of convertible senior notes. While R&D expenses saw a slight decrease, likely due to a reimbursement from a collaboration, overall investment in growth remains evident. Management highlighted advancements in their pipeline, particularly in the HIV and liver disease areas, underscoring a continued commitment to innovation. However, investors should note the impact of U.S. healthcare reform, estimated to reduce net product sales by approximately $200 million in 2010. Additionally, Gilead has undertaken significant stock repurchases and has issued convertible senior notes, demonstrating active capital management. The company's strong financial footing, coupled with a promising pipeline, positions it well for continued growth, though regulatory and market access challenges remain key considerations.
Financial Highlights
52 data points| Revenue | $1.94B |
| Cost of Revenue | $477.58M |
| Gross Profit | $1.39B |
| SG&A Expenses | $250.56M |
| Operating Expenses | $958.58M |
| Operating Income | $979.07M |
| Interest Expense | $33.62M |
| Net Income | $704.88M |
| EPS (Basic) | $0.42 |
| EPS (Diluted) | $0.41 |
| Shares Outstanding (Basic) | 1.67B |
| Shares Outstanding (Diluted) | 1.69B |
Key Highlights
- 1Total revenues increased by 19.7% to $5.95 billion for the first nine months of 2010 compared to the same period in 2009.
- 2Product sales grew by 17% to $5.46 billion for the first nine months of 2010, primarily driven by strong performance in the antiviral franchise (Atripla and Truvada).
- 3Cash, cash equivalents, and marketable securities increased significantly to $5.05 billion by September 30, 2010.
- 4Net income attributable to Gilead stockholders rose by 24.4% to $2.27 billion for the nine months ended September 30, 2010.
- 5The company issued $2.5 billion in convertible senior notes in July 2010 to fund stock repurchases and repay existing debt.
- 6Research and development expenses decreased slightly by 3% for the nine months, largely due to reimbursements from a collaboration.
- 7Gilead is actively managing its capital through significant stock repurchases totaling $3.41 billion in the first nine months of 2010.